Thalidomide in the treatment of multiple myeloma

Małgorzata Rokicka-Piotrowicz

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2001
vol. 5

Send email

Copy url:

abstract:

Thalidomide in the treatment of multiple myeloma

Małgorzata Rokicka-Piotrowicz

Współcz Onkol (2001) vol. 5, 4, 161-164

Online publish date: 2003/07/16

View full text Get citation

More than three decades after its withdrawal from the world market thalidomide is attracting growing interest because of its reported antiangiogenetic, immunomodulatory and anti-inflammatory properties. Recently, the drug was approved for sale in the United States for the treatment of erythrema nodosum leprosum. This review presents a new possibility of treatment of multiple myeloma patients with thalidomide. The dosage and side effects of thalidomide are described.

keywords:

Thalidomide in the treatment of multiple myeloma

Małgorzata Rokicka-Piotrowicz

multiple myeloma, thalidomide, cancer treatment